In spite of intense global competition, Lundbeck has a chance of becoming the first drug company in the world to launch a new drug to treat Alzheimer’s disease.
That is the definite conviction of Anders Gersel Pedersen VP of Research & Development in Lundbeck. It follows a recent announcement revealing that Lundbeck’s Japanese partner Otsuka is planning to test the potential Alzheimer’s treatment, Lu AE58054, in 3,000 patients in four global phase III studies – the final phase of testing prior to approval of a drug. Only a handful of drugs make the cut – and the next one to do so could well be Danish.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app